Erkut Borazanci
Overview
Explore the profile of Erkut Borazanci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis T, Decker K, Hosseini D, Jameson G, Borazanci E
Front Oncol
. 2025 Feb;
15:1495500.
PMID: 39980568
Introduction: Many studies have reported the importance of the human microbiome in relationship to the overall health of its host. While recent studies have explored the microbiome's role in various...
2.
Chung V, Alistar A, Becerra C, Kasi A, Borazanci E, Jameson G, et al.
Oncologist
. 2025 Jan;
30(1).
PMID: 39846984
Lessons Learned: Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life. Background: Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with...
3.
Gardner F, Wainberg Z, Fountzilas C, Bahary N, Womack M, Macarulla T, et al.
Cancers (Basel)
. 2024 Apr;
16(7).
PMID: 38611000
The efficacy and safety of olaratumab plus nabpaclitaxel and gemcitabine in treatment-naïve participants with metastatic pancreatic ductal adenocarcinoma was evaluated. An initial phase 1b dose-escalation trial was conducted to determine...
4.
Shriram J, Stoltz R, Borazanci E
AME Case Rep
. 2024 Jan;
8:22.
PMID: 38234350
Background: Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic carcinomas. Prognosis is poor with a worldwide five-year survival rate of 2-9%. Extent of metastasis is a prognostic factor....
5.
Borazanci E, Saluja A, Gockerman J, Velagapudi M, Korn R, Von Hoff D, et al.
Oncologist
. 2024 Jan;
29(2):132-141.
PMID: 38169017
Background: Minnelide is a water-soluble prodrug of triptolide. Triptolide is an anticancer agent that targets cancer resistance through several mechanisms. Minnelide was evaluated in a phase I study in patients...
6.
Xu C, Jun E, Okugawa Y, Toiyama Y, Borazanci E, Bolton J, et al.
Gastroenterology
. 2023 Oct;
166(1):178-190.e16.
PMID: 37839499
Background & Aims: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies. Delayed manifestation of symptoms and lack of specific diagnostic markers lead patients being diagnosed with PDAC...
7.
Antal C, Oh T, Aigner S, Luo E, Yee B, Campos T, et al.
Nat Commun
. 2023 Sep;
14(1):5195.
PMID: 37673892
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy in need of new therapeutic options. Using unbiased analyses of super-enhancers (SEs) as sentinels of core genes involved in cell-specific function, here...
8.
Hidalgo M, Garcia-Carbonero R, Lim K, Messersmith W, Garrido-Laguna I, Borazanci E, et al.
Cancer Res Commun
. 2023 Mar;
2(11):1326-1333.
PMID: 36970055
Purpose: To assess the preclinical efficacy, clinical safety and efficacy, and MTD of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Experimental Design: Preclinical activity was tested...
9.
Han M, Borazanci E
J Gastrointest Oncol
. 2023 Mar;
14(1):458-462.
PMID: 36915432
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease with a poor prognosis. Despite high efficacy in multiple cancers, immunotherapy has had very little success in treating PDAC due...
10.
Babiker H, Borazanci E, Subbiah V, Agarwala S, Algazi A, Schachter J, et al.
Clin Cancer Res
. 2022 Aug;
28(23):5079-5087.
PMID: 35917516
Purpose: Tilsotolimod is an investigational synthetic Toll-like receptor 9 (TLR9) agonist that has demonstrated antitumor activity in preclinical models. The ILLUMINATE-101 phase I study explored the safety, dose, efficacy, and...